Neuroinflammation: An overview of neurodegenerative and metabolic diseases and of biotechnological studies

AP de Araújo Boleti, TM de Oliveira Flores… - Neurochemistry …, 2020 - Elsevier
Neuroinflammation is an important factor contributing to cognitive impairment and
neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD) …

Back and to the future: from neurotoxin‐induced to human Parkinson's disease models

M Airavaara, I Parkkinen, J Konovalova… - Current Protocols in …, 2020 - Wiley Online Library
Parkinson's disease (PD) is an age‐related neurodegenerative disorder characterized by
motor symptoms such as tremor, slowness of movement, rigidity, and postural instability, as …

Dicer and microRNAs protect adult dopamine neurons

P Chmielarz, J Konovalova, SS Najam, H Alter… - Cell death & …, 2017 - nature.com
MicroRNAs (miRs) are important post-transcriptional regulators of gene expression
implicated in neuronal development, differentiation, aging and neurodegenerative diseases …

GDNF/RET signaling pathway activation eliminates Lewy body pathology in midbrain dopamine neurons

P Chmielarz, Ş Er, J Konovalova, L Bandres… - Movement …, 2020 - Wiley Online Library
Background Parkinson's disease (PD) is associated with proteostasis disturbances and
accumulation of misfolded α‐synuclein (α‐syn), a cytosolic protein present in high …

Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson's disease

AK Mahato, YA Sidorova - Cell and tissue research, 2020 - Springer
Rearranged during transfection (RET), in complex with glial cell line-derived (GDNF) family
receptor alpha (GFRα), is the canonical signaling receptor for GDNF family ligands (GFLs) …

Glial cell line–derived neurotrophic factor receptor rearranged during transfection agonist supports dopamine neurons in vitro and enhances dopamine release in vivo

AK Mahato, J Kopra, JM Renko, T Visnapuu… - Movement …, 2020 - Wiley Online Library
Abstract Background Motor symptoms of Parkinson's disease (PD) are caused by
degeneration and progressive loss of nigrostriatal dopamine neurons. Currently, no cure for …

Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease

P Runeberg-Roos, E Piccinini, AM Penttinen… - Neurobiology of …, 2016 - Elsevier
In Parkinson's disease midbrain dopaminergic neurons degenerate and die. Oral
medications and deep brain stimulation can relieve the initial symptoms, but the disease …

[PDF][PDF] Studying pre-formed fibril induced α-synuclein accumulation in primary embryonic mouse midbrain dopamine neurons

S Er, I Hlushchuk, M Airavaara… - JoVE (Journal of …, 2020 - drive.google.com
The goal of this protocol is to establish a robust and reproducible model of α-synuclein
accumulation in primary dopamine neurons. Combined with immunostaining and unbiased …

Neuroprotective potential of a small molecule RET agonist in cultured dopamine neurons and hemiparkinsonian rats

JM Renko, AK Mahato, T Visnapuu… - Journal of …, 2021 - content.iospress.com
Background: Parkinson's disease (PD) is a progressive neurological disorder where loss of
dopamine neurons in the substantia nigra and dopamine depletion in the striatum cause …

Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism

G Kreiner, K Rafa-Zabłocka, J Barut, P Chmielarz… - Scientific reports, 2019 - nature.com
Parkinson's disease (PD) is the second most common neurodegenerative disorder and is
characterized by motor deficits such as tremor, rigidity and bradykinesia. These symptoms …